Literature DB >> 33393633

Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.

Jacky Yeung1, Vesal Yaghoobi2, Thazin N Aung2, Matthew D Vesely3,4, Tianxiang Zhang4, Patricia Gaule2, Murat Gunel1, David L Rimm2, Lieping Chen4.   

Abstract

The immunological status of human meningiomas is not well understood, hindering the development of rational immunotherapeutic strategies. We measured the levels of PD-L1, PD-L2, and immune cell subsets using multiplex quantitative immunofluorescence in a tissue microarray composed of 73 human meningiomas (56 WHO Grade 1, 13 WHO Grade 2, and 4 WHO Grade 3). We analyzed tumor-infiltrating immune cell populations, T-cell activation/dysfunction, and macrophage phenotypes. PD-L1 and PD-L2 were detected in 5.8% and 68.7% of cases, respectively. There was a higher PD-L1 expression in CD68+ macrophages compared with tumor cells (p < 0.001). There was a weak positive correlation between PD-L1 expression and CD3+ T-cell infiltration. The level of CD3+ cells and T-cell activation/proliferation in human meningiomas were highly variable with an increased CD4-to-CD8 ratio in higher grade tumors (p < 0.05). There was a stronger correlation between GZMB/Ki67 with PD-L2 than PD-L1. We found that 15.23%, 6.66%, and 5.49% of macrophages were CD163+, CD68+, and CD163+CD68+, respectively. In cases where there is high CD3+ T-cell infiltration, 23.5% and 76.5% had dormant and activated T-cell phenotypes, respectively. We conclude that human meningiomas are either PD-L1low TILlow or PD-L1low TILhigh tumors and harbor variable TIL infiltration and phenotypes.
© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Immunology; Meningioma; Tumor microenvironment

Year:  2021        PMID: 33393633     DOI: 10.1093/jnen/nlaa152

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  5 in total

Review 1.  Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review.

Authors:  Nivedha V Kannapadi; Pavan P Shah; Dimitrios Mathios; Christopher M Jackson
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.

Authors:  Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 12.300

3.  Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.

Authors:  Jacky Yeung; Vesal Yaghoobi; Danielle Miyagishima; Matthew D Vesely; Tianxiang Zhang; Ti Badri; Ala Nassar; Xue Han; Miguel F Sanmamed; Mark Youngblood; Matthieu Peyre; Michel Kalamarides; David L Rimm; Murat Gunel; Lieping Chen
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 12.300

4.  Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.

Authors:  Priscilla K Brastianos; Albert E Kim; Anita Giobbie-Hurder; Eudocia Quant Lee; Nancy Wang; April F Eichler; Ugonma Chukwueke; Deborah A Forst; Isabel C Arrillaga-Romany; Jorg Dietrich; Zachary Corbin; Jennifer Moliterno; Joachim Baehring; Michael White; Kevin W Lou; Juliana Larson; Magali A de Sauvage; Kathryn Evancic; Joana Mora; Naema Nayyar; Jay Loeffler; Kevin Oh; Helen A Shih; William T Curry; Daniel P Cahill; Fred G Barker; Elizabeth R Gerstner; Sandro Santagata
Journal:  Nat Commun       Date:  2022-03-14       Impact factor: 14.919

Review 5.  The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas.

Authors:  Giuseppe Roberto Giammalva; Lara Brunasso; Federica Paolini; Roberta Costanzo; Lapo Bonosi; Umberto Emanuele Benigno; Gianluca Ferini; Serena Sava; Cristina Colarossi; Giuseppe Emmanuele Umana; Rosa Maria Gerardi; Carmelo Lucio Sturiale; Alessio Albanese; Domenico Gerardo Iacopino; Rosario Maugeri
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.